HCID 18753453, compound → HCID 22478243, compound
Reaction equation
[Cl:1][C:2]1[CH:26]=[CH:25][C:5]([NH:6][C:7]2[C:16]3[C:11](=[CH:12][C:13]([O:19][CH2:20][CH2:21][CH2:22][S:23][CH3:24])=[C:14]([O:17][CH3:18])[CH:15]=3)[N:10]=[CH:9][N:8]=2)=[C:4]([F:27])[CH:3]=1.[OH:28]OS([O-])=O.[K+]>>[Cl:1][C:2]1[CH:26]=[CH:25][C:5]([NH:6][C:7]2[C:16]3[C:11](=[CH:12][C:13]([O:19][CH2:20][CH2:21][CH2:22][S:23]([CH3:24])=[O:28])=[C:14]([O:17][CH3:18])[CH:15]=3)[N:10]=[CH:9][N:8]=2)=[C:4]([F:27])[CH:3]=1Participants
3
Procedure
Using a method analogous to that in Example 25, 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-methylthiopropoxy)quinazoline (250 mg, 0.6 mmol), (prepared as described in Example 21), was treated with OXONE, (trade mark of E.I. du Pont de Nemours & Co., Inc), (84 mg) and the product was pied and isolated to give 4-(4-chloro-2-fluoroanilino)-6-methoxy-7-(3-methylsulphinylpropoxy)quinazoline (75 mg, 29%).
Workup
- customisolated
Sources & evidence
- ORD record
- ord-c038dc67ec6244dd98f8af3aa8b2c3e9
- Source dataset
- uspto-grants-2011_05
- Patent number
- USRE042353E1
Reaction notes
Loading…